Almost no side effects: Only 2% of children had symptoms after the vaccine Israel today

Only 2% of children aged 5 to 11 who were vaccinated for corona in a second dose reported side effects after the vaccine and like adults, more side effects were reported after the second dose.

Five-year-olds reported fewer side effects than 11-year-olds.

The survey also shows that 70% of children reported local side effects (such as pain at the injection site), with no difference between first and second dose.

A third of children suffered from general symptoms such as weakness, fatigue and headaches (compared with 20% after the first vaccination).

In half of the vaccinated, the side effects passed within a day of the second vaccine and in 85% within three days.

It was also found that the rate of side effects was higher among 11-year-olds. About a quarter of them (26%) reported loss of schooling or afternoon activity after the second dose (twice as much as after the first dose).

18% reported headaches, 21% weakness and fatigue and 60% had no symptoms at all.

Among 5-year-olds, 75% had no symptoms at all after a second dose.

13% reported weakness and fatigue, 8% reported headaches and 11% missed school or class because they did not feel well after the second dose of vaccine.

"Feeling much safer when going out to events": Vaccines for the second dose for children at the Maccabi Health Insurance Fund

Dr. Miri Mizrahi Reuveni, head of Maccabi's medical department, commented on the side effects and explained: "There were no hospitalizations following the vaccine, there were only referrals to clinics with a report.

"In comparing the data, we saw that there are fewer side effects in children aged 5 than in children aged 11 and we estimate that when the vaccine is approved for children under the age of five, so will they."

Abnormal load in the test complexes

Meanwhile, Maccabi presented data showing that they had passed the existing capabilities to perform laboratory tests and return answers within a reasonable time.

The director of the nursing department at Maccabi, Tamar Alkalay: "We have been performing 34-37 thousand samples in the last few days, with a capacity of 33,000. Already today the time for the result has been damaged and we are waiting for the Ministry of Health to announce PCR tests for at-risk population only."

"The state of Israel can not do more PCR tests than it can today, it is clear. And since there is a window of opportunity to give preventive treatment to the at-risk population, we want to reach these people and give the drug within 5 "3 days. A public decision on the issue is required."

Minister of Health with Israeli children vaccinated against corona, archive,

Dr. Arnon Shachar, Medical Director of the Corona Struggle at Maccabi and Member of the IDF: He noted that Maccabi has the ability to treat 200 Corona patients in moderate to severe condition as part of a home hospitalization.

Between the third and fourth wave, we dropped from 3% hospitalizations to 2%, and it happened because Maccabi and the rest of the funds became better. "

We need a statement from the state and this is a completely budgetary matter so that we can be more hospitalized. "

Maccabi stated that in recent days they have begun giving the preventive treatment to Corona Paxlobid, which reduces the risk of hospitalization or mortality by 90%.

Treatment will be given to 20% of those infected by the high-risk cable algorithm.

The index consists of age, along with diseases such as diabetes hypertension, immunosuppression, obesity and also the state of the vaccine and distance from the last vaccine.

To date, 13% of refusals to receive treatment have been recorded.

Dr. Shachar noted that “in this wave we are together with a fourth dose, boosters, antibodies and new drugs.

It is difficult to estimate how many will come to the hospitals.

If the public uses the tools we provide, we can provide good medical service to the right people and reduce the burden on hospitals. "

Were we wrong?

Fixed!

If you found an error in the article, we'll be happy for you to share it with us